Erythropoietin doubles the incidence of microvascular obstruction in primary PCI - a randomized controlled trial in acut
- PDF / 638,753 Bytes
- 2 Pages / 610 x 792 pts Page_size
- 26 Downloads / 194 Views
BioMed Central
Open Access
Oral presentation
Erythropoietin doubles the incidence of microvascular obstruction in primary PCI - a randomized controlled trial in acute MI using CMR primary endpoints Andrew J Ludman*1, Jonathan M Hasleton1, Girish Babu1, Edney BostonGriffiths1, James C Moon2, Vivek Muthurangu3, Andrew M Taylor3, Raj Puranik3, Derek M Yellon1 and Derek J Hausenloy1 Address: 1The Hatter Cardiovascular Institute, University College of London, London, UK, 2University College of London, London, UK and 3Great Ormond Street Hospital, London, UK * Corresponding author
from 13th Annual SCMR Scientific Sessions Phoenix, AZ, USA. 21-24 January 2010 Published: 21 January 2010 Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O78
doi:10.1186/1532-429X-12-S1-O78
Abstracts of the 13th Annual SCMR Scientific Sessions - 2010
Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/files/pdf/1532-429X-11-S1-infoThis abstract is available from: http://jcmr-online.com/content/12/S1/O78 © 2010 Ludman et al; licensee BioMed Central Ltd.
Introduction Previous animal studies have reported that the acute administration of EPO at the onset of myocardial reperfusion reduces infarct size by 40-50%. Whether EPO has the same effect in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI) is unknown.
Purpose To assess the efficacy of erythropoietin (EPO) as adjunctive therapy to PPCI in STEMI patients using cardiac magnetic resonance (CMR) endpoints.
face area-ESA) were performed at day 3 and repeated at 4 months.
Results The groups were matched with no differences in chest pain to balloon time or area at risk (AAR) by coronary angiography (modified BARI and APPROACH jeopardy scores) or CMR (infarct-ESA). There were no significant differences with respect to LVEF, myocardial infarct size, or the myocardial salvage index (see table 1). However, EPO treatment doubled the incidence of MVO and acutely increased LV size (indexed LV end diastolic and systolic
Methods Fifty one STEMI patients presenting for PPCI within 12 hours of chest pain were randomized to receive either a single intravenous bolus of EPO (50,000 iu in 10 mls normal saline) with a further bolus given 24 hours later, or placebo. Patients with TIMI flow>1, cardiac arrest, cardiogenic shock or significant coronary collateralization were excluded. Both patient and cardiologist were blinded to the treatment allocation. Troponin-T and CK-MB were measured over 24 hours. CMR scans (LV volumes, LV ejection fraction-EF, late gadolinium enhancement-LGE, microvascular obstruction-MVO, infarct-endocardial sur-
Figure 1
Page 1 of 2 (page number not for citation purposes)
Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O78
http://jcmr-online.com/content/12/S1/O78
Table 1: CMR endpoints day 3 post-PPCI
Endpoint
Placebo
Erythropoietin
P value
LVEF
53 ± 11%
51 ± 7%
P = 0.26
24 hr AUC Trop-
Data Loading...
